drug_type
RELEVANT_DRUG
intervention_type
Adoptive cellular therapy (TIL)
drug_description
Autologous, non–genetically modified tumor-infiltrating lymphocyte (TIL) therapy providing ex vivo expanded tumor‑reactive T cells to mediate cytotoxicity against tumor cells.
nci_thesaurus_concept_id
C200810
nci_thesaurus_definition
A preparation of autologous tumor infiltrating lymphocytes (TILs) derived from each patients resected tumor and expanded ex vivo, with potential immunomodulating and antineoplastic activities. Upon administration back into the patient, autologous TILs HV-101 specifically recognize and kill the patients tumor cells.
drug_mesh_term
Lymphocytes, Tumor-Infiltrating
drug_category
TUMOR INFILTRATING LYMPHOCYTES
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous, non-genetically modified tumor-infiltrating lymphocytes expanded ex vivo; upon reinfusion, native TCRs recognize patient-specific tumor antigens and mediate cytotoxic killing of tumor cells via perforin/granzyme release and cytokine-driven immune activation.
drug_name
HV-101
nct_id_drug_ref
NCT05868915